ERN1 and Other metabolic disease: Targeting ER stress/IRE1α has thus been proposed for its potential in countering obesity and obesity-related metabolic disorders including insulin resistance and type 2 diabetes (Hetz et al., 2013; Marciniak et al., 2022).